A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Piclozotan (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Asubio Pharmaceuticals
- 14 Jun 2008 Status changed from in progress to discontinued.
- 08 Nov 2006 New trial record.